Nightingale HealthNGHLF 52 EBITDA Margin % is -206.09% as of Dec. 2025. GuruFocus rates NGHLF with a GF Score™ of 52/100 and a GF Value™ of $2.64 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Nightingale Health ranks worse than 94.01% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nightingale Health's EBITDA for the
six
months ended in Dec. 2025 was $-5.82 Mil. Nightingale Health's Revenue for the
six
months ended in Dec. 2025 was $2.82 Mil. Therefore, Nightingale Health's EBITDA margin for the quarter that ended in Dec. 2025 was -206.09%.
Nightingale Health (OTCPK:NGHLF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nightingale Health EBITDA Margin % Related Terms
Nightingale Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nightingale Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGHLF vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Nightingale Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nightingale Health EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nightingale Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nightingale Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nightingale Health (NGHLF) has a EBITDA Margin % of -206.09% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nightingale Health and its competitors. According to the industry distribution chart, Nightingale Health ranks #628 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 94%.
Is Nightingale Health's EBITDA Margin % too high?
Nightingale Health's current EBITDA Margin % is -206.09%. Based on the distribution chart, Nightingale Health ranks #628 out of 668 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Nightingale Health has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nightingale Health's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Nightingale Health ranks #628 out of 668 companies for EBITDA Margin %. This places Nightingale Health in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nightingale Health and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nightingale Health's current EBITDA Margin % is -206.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nightingale Health stock overvalued right now?
Based on GuruFocus' analysis, Nightingale Health (NGHLF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.64, compared to a current price of $1.19 — trading 54.9% below its estimated fair value. The current EBITDA Margin % is -206.09%. Nightingale Health's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nightingale Health (NGHLF), the current EBITDA Margin % is -206.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nightingale Health (NGHLF) Overvalued in 2026?
Based on GuruFocus' analysis, Nightingale Health stock appears to be undervalued.
The current stock price of $1.19 is trading 54.9% below its estimated GF Value™ of $2.64.
GuruFocus considers Nightingale Health to be Possible Value Trap.
Key valuation signals for NGHLF:
EBITDA Margin %: -206.09%
GF Value™: $2.64 vs. price of $1.19 (54.9% below fair value)
No single metric tells the full story. See the NGHLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nightingale Health PLC offers a health data platform that detects disease risks. The Health Data Platform empowers individuals to take actions to prevent diseases by allowing them access to disease risk information. With its Health Data Platform, the company connects the services of healthcare actors with the preventative health needs of individuals. The company operates in Finland, Japan, the United Kingdom, Singapore, and the USA.
52GF Score
Get the complete analysis for NGHLF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGHLF has been successfully added to your 
